CL2011000135A1 - Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica. - Google Patents

Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.

Info

Publication number
CL2011000135A1
CL2011000135A1 CL2011000135A CL2011000135A CL2011000135A1 CL 2011000135 A1 CL2011000135 A1 CL 2011000135A1 CL 2011000135 A CL2011000135 A CL 2011000135A CL 2011000135 A CL2011000135 A CL 2011000135A CL 2011000135 A1 CL2011000135 A1 CL 2011000135A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
surfactant
treating
terbinafine
fungal infection
Prior art date
Application number
CL2011000135A
Other languages
English (en)
Inventor
Gregor Vierl Ulrich Cevc
Original Assignee
Targeted Delivery Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Delivery Tech Limited filed Critical Targeted Delivery Tech Limited
Publication of CL2011000135A1 publication Critical patent/CL2011000135A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para tratar una infección fúngica con una formulación que comprende terbinafina, un lípido y un tensoactivo; una formulación farmacéutica; un kit; un método para tratar una infección fúngica con una formulación tópica que comprende un compuesto de fórmula I, un lípido y un tensoactivo y la formulación farmacéutica.
CL2011000135A 2008-07-23 2011-01-21 Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica. CL2011000135A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8311508P 2008-07-23 2008-07-23
US10211108P 2008-10-02 2008-10-02
US15018709P 2009-02-05 2009-02-05
US16812209P 2009-04-09 2009-04-09

Publications (1)

Publication Number Publication Date
CL2011000135A1 true CL2011000135A1 (es) 2011-09-23

Family

ID=41358304

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000135A CL2011000135A1 (es) 2008-07-23 2011-01-21 Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.

Country Status (15)

Country Link
US (2) US20100086504A1 (es)
EP (1) EP2317993A2 (es)
JP (1) JP2011529038A (es)
KR (1) KR20110039357A (es)
CN (1) CN102159202A (es)
AU (1) AU2009275230A1 (es)
CA (1) CA2731455A1 (es)
CL (1) CL2011000135A1 (es)
CO (1) CO6351719A2 (es)
EC (1) ECSP11010818A (es)
IL (1) IL210813A0 (es)
MX (1) MX2011000932A (es)
NI (1) NI201100025A (es)
PE (1) PE20110642A1 (es)
WO (1) WO2010010470A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676975A1 (en) * 2007-02-05 2008-08-14 Biophile Corporation, Ltd. Increased effectiveness of allylamine drug compounds
RU2011136624A (ru) * 2009-02-05 2013-03-10 Тарджетед Деливери Текнолоджиз Лимитед Способы уменьшения пролиферации и жизнеспособности микробных агентов
FR2954163B1 (fr) * 2009-12-18 2012-03-16 Galderma Pharma Sa Utilisation d'un tensioactif cationique, avantageu-sement amphotere, pour la preparation d'une composition antifongique applicable sur l'ongle
AU2010336441B2 (en) 2009-12-23 2015-02-05 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
CN103384518B (zh) 2011-02-11 2018-10-26 莫贝里制药公司 新的抗真菌组合物
US20140017302A1 (en) * 2011-03-21 2014-01-16 Gregor Cevc Optimised preparations of highly adaptable aggregates
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
US8697753B1 (en) * 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
WO2015138926A1 (en) 2014-03-14 2015-09-17 Gojo Industries, Inc. Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines
AT516544B1 (de) 2014-12-02 2017-05-15 Universität Innsbruck Stoffgemisch und Zubereitung
CN105193726B (zh) * 2015-11-08 2018-01-26 长沙佰顺生物科技有限公司 一种治疗灰指甲的药物组合物
KR101952715B1 (ko) * 2017-09-27 2019-02-27 경희대학교 산학협력단 천연 화합물을 포함하는 칸디다증 개선용 항진균 조성물
RU2698454C1 (ru) * 2018-11-12 2019-08-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ лечения онихомикозов стоп
KR102072946B1 (ko) 2019-08-06 2020-02-03 주식회사 씨엔엘바이오텍 조갑진균증 예방 또는 치료용 조성물
WO2021072027A1 (en) * 2019-10-08 2021-04-15 Hallux Inc. Onychomycosis treatment compositions and methods
AT524378A1 (de) 2020-11-06 2022-05-15 Univ Innsbruck Zubereitung
CA3201760A1 (en) * 2020-12-08 2022-06-16 Torbjorn Warnheim Treatment regimen for onchyomycosis using allylamine antifungal compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19975055I1 (de) * 1979-08-22 2000-01-27 Novartis Ag Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwending als Arzneimittel
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
ATE267613T1 (de) * 1998-03-05 2004-06-15 Phares Pharm Res Nv Arzneimittel und deren verwendung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
EA011244B1 (ru) * 2004-03-18 2009-02-27 Панацея Биотек Лтд. Новые композиции для местной доставки
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
JP5467722B2 (ja) * 2007-01-16 2014-04-09 ロート製薬株式会社 皮膚外用乳化製剤
CA2676975A1 (en) * 2007-02-05 2008-08-14 Biophile Corporation, Ltd. Increased effectiveness of allylamine drug compounds

Also Published As

Publication number Publication date
CN102159202A (zh) 2011-08-17
CO6351719A2 (es) 2011-12-20
PE20110642A1 (es) 2011-08-31
KR20110039357A (ko) 2011-04-15
WO2010010470A3 (en) 2010-03-18
IL210813A0 (en) 2011-04-28
WO2010010470A2 (en) 2010-01-28
US20100104633A1 (en) 2010-04-29
EP2317993A2 (en) 2011-05-11
US20100086504A1 (en) 2010-04-08
ECSP11010818A (es) 2011-05-31
US7820720B2 (en) 2010-10-26
AU2009275230A1 (en) 2010-01-28
CA2731455A1 (en) 2010-01-28
JP2011529038A (ja) 2011-12-01
NI201100025A (es) 2011-11-02
MX2011000932A (es) 2011-05-19

Similar Documents

Publication Publication Date Title
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
DOP2012000261A (es) Formulaciones de insulina de accion prolongada
CL2012003229A1 (es) Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
UY30440A1 (es) Nuevos compuestos
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
DOP2010000387A (es) Compuestos pirazolicos 436
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
AR084285A1 (es) Composiciones inmunogenicas
CL2011000561A1 (es) Formulacion farmaceutica que comprende un anticuerpo contra p-selectina, un regulador de ph, un agente tensoactivo, un estabilizador; uso de dicha formulacion para tratar el asma o alergia.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
AR101581A1 (es) Composición de colutorio
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.